Core Points - Addex Therapeutics will release its Q1 2024 financial results on June 6, 2024, and will provide a business update and product pipeline review during a teleconference and webcast [1] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on the same day [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, ADX71149, is a positive allosteric modulator (PAM) for mGlu2 and has completed a Phase 2 clinical study for epilepsy [3] - The second clinical program, dipraglurant, is a negative allosteric modulator (NAM) for mGlu5, under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior to advance multiple drug candidates for substance use disorder and is also developing a GABAB PAM program for chronic cough [3] - The company holds a 20% share in Neurosterix LLC, which is advancing several allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024